Studies of thrombectomy devices made by Medtronic's Covidien, Stryker and Penumbra show that they dramatically improve the likelihood that patients will recover from stroke.
(Reuters) - Grabbing and removing a clot blocking blood flow to the brain via thrombectomy, rather than just administering clot-busting drugs, dramatically improves the likelihood that patients will recover from a stroke, according to 2 highly-anticipated studies released today.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Medtronic's new Ev3 unit pays $1.3m in whistleblower suit; GPOs: Premier buys the rest of direct sourcer S2S Global; CareFusion crushes it in final quarter; BD beats Q1 estimates, raises outlook, shares jump; Zimmer revises Biomet bid for EU regulators
A labeling miscue prompts Covidien to recall 2 models of its Trellis clot-busting infusion device.
UPDATED Feb. 12, 2015, with new information from Medtronic.
Results from a study of Medtronic's ClosureFast varicose vein device, published this month in the British Journal of Surgery, show an 91.9% occlusion rate after 5 years.
Here's a look at some of the top regulatory stories for medical device companies this week: Regulators deal Wright Medical a double whammy; Medtronic wins FDA approval for Melody pulmonary valve; FDA approves Cohera's TissuGlu surgical sealant; FDA approves Medtronic's Pipeline Flex aneurysm device; Sorin wins MRI-safe pacemaker approval in Japan
Medtronic agrees to settle for $1.25 million a whistleblower lawsuit inherited from the Ev3 subsidiary it acquired in the $50 billion Covidien deal.
The FDA grants pre-market approval for the Pipeline Flex device for treating brain aneurysms Medtronic acquired along with Covidien.